News

Cadrenal’s Quiet Expansion Play Is Starting to Get Loud

PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) entered the back half of the…

2 weeks ago

Cadrenal’s Anticoagulation Platform Is Expanding in a $40 Billion Market

PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) believes it continues to be misread…

2 weeks ago

NanoVibronix, Inc. Announces Name and Ticker Symbol Change to ENvue Medical, Inc. and ‘FEED’

New ticker symbol, “FEED” will begin trading on the Nasdaq at the open of the market on December 12, 2025…

2 weeks ago

Smart Meter and eClinicalWorks More Than Double RPM Adoption in 2025, Powering a New Era of Connected Care for Patients

TAMPA, Fla.--(BUSINESS WIRE)--Smart Meter, the leader in Cellular RPM™ and the nation’s most trusted source of patient-generated vital health data,…

2 weeks ago

BrainCheck Awarded $500K NIH SBIR Phase I Grant to Advance eConsult Platform for Cognitive Care

AUSTIN, Texas--(BUSINESS WIRE)--#CognitiveHealth--BrainCheck, the leading FDA Class II digital cognitive assessment and care platform, has been awarded a $500,000 SBIR…

2 weeks ago

VSee Health, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement

SAN JOSE, CALIFORNIA / ACCESS Newswire / December 12, 2025 / VSee Health, Inc. (Nasdaq:VSEE, VSEEW), a leading provider of…

2 weeks ago

Parexel Named “Best Contract Research Organization” at 21st Annual Scrip Awards

Industry leader recognized for excellence and innovation in clinical developmentRALEIGH, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading…

2 weeks ago

Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability…

2 weeks ago

Additional Confirmed Response Reported as Part of Amplia Investor Presentation

HIGHLIGHTS An additional confirmed partial response has been recorded in the ongoing ACCENT trialThis brings the confirmed Objective Response Rate…

2 weeks ago

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics,…

2 weeks ago